Xiaoyin Keli (消银颗粒)消银颗粒

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

地黄 牡丹皮 赤芍 当归 苦参 金银花 玄参 牛蒡子 蝉蜕 白鲜皮 防风 大青叶 红花是一种在国家药监局注册认定的药品。该药品含有地黄、大青叶、当归-955c5af6等成分。

该药品关联的活性成分包括:地黄rehmannia、大青叶Daqing Ye、当归Dang Gui、牛蒡子Niubang Zi、牡丹皮Mudan Pi。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:陕西康惠制药股份有限公司Chinese legal name: 陕西康惠制药股份有限公司。

您可以探索含有相同成分的其他药品:地黄-2fcdf084成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 消银颗粒) is a medicine registered with the national drug regulatory authority. It contains rehmannia and other recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 地黄rehmannia, 大青叶Daqing Ye, 当归Dang Gui, 牛蒡子Niubang Zi, 牡丹皮Mudan Pi.

Manufacturers recorded for this product: 陕西康惠制药股份有限公司Chinese legal name: 陕西康惠制药股份有限公司.

Explore other medicines containing the same ingredient: 地黄 productsrehmannia products.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 消银颗粒Recorded Chinese name: 消银颗粒
  • 剂型Dosage form: 颗粒剂Granules
  • 规格Specification: 3.5g*10袋3.5 g × 10 sachets

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 陕西康惠制药股份有限公司Chinese legal name: 陕西康惠制药股份有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字Z20000019

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字Z20000019

Manufacturer

Chinese legal name: 陕西康惠制药股份有限公司 (domestically manufactured)

Traditional functions

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep sealed.

Specification

3.5 g × 10 sachets

中文说明书原文Original Chinese source label

批准文号

国药准字Z20000019

生产企业

陕西康惠制药股份有限公司(国产)

功能主治

1.银屑病(牛皮癣):症见皮疹基底鲜红,或上覆白色鳞屑,瘙痒,反复发作。|2.对湿疹,荨麻疹,扁平疣等皮肤病也有显著疗效。

用法用量

开水冲服,一次3.5g,一日3次。一个月为一疗程。

不良反应

尚不明确。

禁忌

对本品过敏者禁用。

注意事项

尚不明确。

贮藏

密封。

规格

3.5g*10袋

证据Evidence

  • 批准文号: 国药准字Z20000019
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.